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Abstract
Background: Bacterial vaginosis (BV) affects 30–50% of women at some time in their lives and is an embarrassing
and distressing condition which can be associated with potentially serious comorbidities. Current antibiotic
treatments such as metronidazole are effective but can result in side effects, and recurrence is common. This trial
aims to investigate whether lactic acid gel is clinically effective and cost effective in the treatment of recurrent BV
compared with metronidazole.
Methods: VITA is an open-label, multicentre, parallel group randomised controlled trial for women with a clinical
diagnosis of BV and at least one previous BV episode in the past 2 years. Participants will be randomised 1:1 to
intravaginal lactic acid gel 5 ml once daily for 7 days or oral metronidazole tablets 400 mg twice daily for 7 days. All
participants will be followed up for 6 months to assess health status and healthcare costs. A subgroup will be
interviewed to further explore adherence, tolerability and acceptability of treatment. The estimated sample size is
1900 participants to detect a 6% absolute increase in response rate to 86% in those receiving lactic acid gel. The
primary outcome is participant-reported resolution of BV at Week 2.
Discussion: Results from this trial will help inform UK treatment guidelines for BV and may provide an alternative
effective treatment for recurrent episodes of this condition which avoids repeated exposure to antibiotics.
Trial registration: ISRCTN, ISRCTN14161293. Registered on 8 September 2017.
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Background
Bacterial vaginosis (BV) is a common condition which
causes an offensive smelling vaginal discharge and is as-
sociated with an increased risk of HIV acquisition and
transmission, pelvic inflammatory disease and adverse
pregnancy outcomes [1–4]. The normal bacteria found
in the vagina include numerous lactobacilli which pro-
duce lactic acid maintaining a low pH and inhibiting the
growth of other bacteria. In BV the pH rises in associ-
ation with loss of lactobacilli and there is an overgrowth
of anaerobic bacteria.
Current treatment with oral antibiotics to reduce the
associated overgrowth of bacteria in the vagina can be
effective in the short term, but it is frequently associated
with side effects and 30% rate of recurrence over the
subsequent 3 months [5–8], necessitating repeated anti-
biotic treatment. Knowledge of the underlying pathogen-
esis of BV is limited and the factor(s) initiating BV are
unknown, although viral bacteriophages, novel sexually
transmitted bacteria, bacterial biofilms and disruption to
the bacterial microbiome have all been proposed [9].
BV was diagnosed in 100,636 women attending sexual
health clinics in England in 2014, and around 30,000
women will have recurrent BV within 3 months of their
initial treatment. The prevalence of BV has not changed
significantly over the past 5 years (https://www.gov.uk/
government/statistics/sexually-transmitted-infections-stis-
annual-data-tables).
The recurrent nature of BV leads to frequent use of
antibiotics. The use of lactic acid gel as treatment would
reduce antibiotic exposure in the population as recom-
mended in the ‘Action plan to support the UK anti-
microbial resistance strategy 2013 to 2018’ (www.gov.uk/
government/publications/uk-5-year-antimicrobial-resist-
ance-strategy-2103-to-2018) and the ‘European strategic
action plan on antibiotic resistance 2011–2016’
(www.euro.who.int/_data/assets/pdf_file/0011/148988/
RC61_Pres_Rodier_antibiotic_resistance.pdf).
Lactic acid gel (pH 4.5) used intravaginally replicates
the production of lactic acid by lactobacilli in the nor-
mal vagina. Previous small studies of daily intravaginal
acid gel or pessary for the treatment of BV have
reported inconsistent results, with efficacy ranging be-
tween 18 and 100% [6, 10–15]. The regimen used most
commonly in previous trials was once daily application
for 1 week, and an increased frequency of dosing did
not affect the response rate (efficacy 23–93% for once
daily versus 18–100% for twice daily). To permit com-
parison with previous trials, to maximise participant ac-
ceptability and because the effectiveness of this regimen
remains unconfirmed, we propose using 4.5% lactic acid
gel inserted intravaginally once a day for 7 days. Al-
though the use of topical lactic acid gel is not recom-
mended in current BV treatment guidelines due to a
lack of evidence from well-designed randomised trials
[7], the proposed trial will advance our understanding
by assessing whether intravaginal lactic acid gel is ef-
fective and well tolerated for the treatment of recurrent
BV, and can reduce antibiotic usage in this large group
of women.
The factors affecting the acceptability of topical treat-
ment for BV are not known, and a qualitative assessment
of adherence to and acceptability of treatment, and how
these can be improved, will be performed.
BV is a common disease with serious physical and psy-
chological sequelae. There is therefore the potential for
substantial health gain if a more effective and well-
tolerated regimen can be identified, which also reduces
antibiotic exposure. The prospects for the study findings
to influence clinical practice are high based on the mul-
ticentre approach including primary care, robust study
design, existing availability of lactic acid gel and identi-
fied need to limit antibiotic use to reduce the develop-
ment of antimicrobial resistance.
Justification for design
This trial will compare the effectiveness, tolerability, ad-
herence, acceptability and cost effectiveness in partici-
pants with BV randomised to intravaginal lactic acid gel
(intervention) versus those randomised to oral metro-
nidazole (control). A pragmatic trial design is used to
maximise its relevance to patients and clinicians and to
facilitate rapid adoption into clinical practice. A qualita-
tive assessment will also investigate the acceptability of
treatment, and if necessary, address issues raised by
participants.
A superiority design has been chosen and powered to
detect an absolute difference of 6% in the resolution of
BV between the two treatment arms, with an assumed
effectiveness of oral metronidazole of 80% [16–19].
There will be no blinding of participants to treatment,
as this will maximise treatment compliance and allow
comparison of the acceptability of the two treatments. A
double placebo (“double dummy”) design for oral versus
vaginal modes of treatment delivery was not considered
to be acceptable to most women.
Participants will take their own vaginal samples at
baseline and at the Week 2 follow-up. The taking of
such samples is widely used in clinical practice and is ac-
ceptable to women. At their baseline visit, participants
will be instructed on how to take their own vaginal sam-
ples; they will then take their own baseline samples,
which will be shipped to a central laboratory by site staff.
Before they leave the clinic (or General Practitioner [GP]
practice), participants will be provided with a second
sampling kit and instructions for taking their own vagi-
nal samples at home at Week 2.
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After the baseline visit, participants will not be re-
quired to attend any further face-to-face visits, reflecting
usual clinical practice. All follow-up data will be col-
lected by participants via online questionnaires.
Choice of treatment
The aim of this trial is to determine if using lactic acid
gel in the vagina to ‘replace’ vaginal acidity is better
than oral metronidazole for treatment of BV. Some pre-
vious studies have suggested that this approach could
be successful, but they are not conclusive, and current
guidelines highlight a need for more evidence before
recommending the use of intravaginal lactic acid gel.
Previous small studies of daily intravaginal acid gel or
pessary for the treatment of BV have reported inconsist-
ent results with efficacies of 18–100% [6, 10–15, 20].
The regimen used most commonly in previous trials was
once daily application for 7 days, and an increased fre-
quency of dosing did not affect the response rate (effi-
cacy 23–93% for once/day compared with 18–100% for
twice/day). To permit comparison with previous trials,
the intervention group will receive a regimen of lactic
acid gel inserted intravaginally once a day for 7 days, to
maximise participant acceptability and because the ef-
fectiveness of this regimen remains unconfirmed.
If effective, the use of lactic acid gel will result in de-
creased antibiotic treatment use, which will maintain
the balance between the gut bacteria (microbiome) for
individual participants and reduce the potential for de-
velopment of antimicrobial resistance in the commu-
nity. In addition, it will provide an alternative treatment
for women who have failed to respond to current treat-
ment for BV with systemic antibiotics.
The control group will receive a 7-day course of twice
daily 400 mg oral metronidazole. This has been chosen
as the comparator because it is recommended as first
line therapy in the UK national BV treatment guideline
[7], it is active against a wide range of the anaerobic bac-
teria associated with BV and it is commonly used in
clinical practice supported by evidence from randomised
controlled trials [18].
Methods/design
Aims and objectives
The trial hypothesis is that intravaginal lactic acid gel is
clinically effective and cost effective in the treatment (i.e.
resolution of symptoms) of women with recurrent BV
compared with oral metronidazole. The aim is to test
this hypothesis by comparing symptom resolution in the
intervention group (receiving intravaginal lactic acid gel)
with the control group (receiving oral metronidazole) for
women with recurrent BV.
The primary objective of the trial is to determine
whether intravaginal lactic acid gel is better than oral
metronidazole for symptomatic resolution of recurrent
BV. Secondary objectives include the following: com-
paring the time to first recurrence of BV symptoms;
comparing the frequency of BV episodes over 6 months;
comparing the frequency of BV treatments required
over 6 months; comparing microbiological resolution of
BV on microscopy 2 weeks after presentation; compar-
ing the tolerability profiles of lactic acid gel and metro-
nidazole; comparing adherence to lactic acid gel versus
metronidazole tablets; comparing acceptability of use of
lactic acid gel versus metronidazole tablets; determining
comparative presence of concurrent sexually transmit-
ted infections (STIs) at baseline and at Week 2; com-
paring quality of life (measured using the SF-12™
Health Survey [21]); comparing the cost effectiveness of
using intravaginal lactic acid gel versus oral metronida-
zole tablets. In addition, samples for further microbio-
logical analysis, including gene sequencing, will be
collected for future investigation into the factors associ-
ated with successful treatment.
Outcome measures
The primary outcome is resolution of BV based on
participant-reported resolution of symptoms at Week 2.
Secondary outcome measures are as follows: time to
first recurrence of BV; number of participant-reported
BV episodes over 6 months; number of participant-
reported BV treatment courses over 6 months; micro-
biological resolution of BV on microscopy of vaginal
smears at Week 2; comparative tolerability of lactic acid
gel and metronidazole assessed by web-based partici-
pant reporting of side effects (including nausea, vomit-
ing, taste disturbance, vaginal irritation, diarrhoea and
abdominal pain) and via participant telephone inter-
views; participant-reported adherence to treatment; ac-
ceptability of treatments via qualitative assessment in a
subgroup of participants; prevalence of concurrent STIs
(gonorrhoea, chlamydia and trichomoniasis) at baseline
and at Week 2; quality of life as assessed by SF-12™
Health Survey at baseline, Week 2 and 6 months; com-
parative cost effectiveness of using intravaginal lactic
acid gel versus oral metronidazole tablets via National
Health Service (NHS) Service use questionnaire.
Design and setting
This is an open-label, multicentre, parallel group, rando-
mised controlled trial. Participants will be randomised 1:
1 to receive either intravaginal lactic acid gel treatment
or oral metronidazole tablets.
Women will be recruited from primary care (GP) prac-
tices and sexual health outpatient and gynaecology
clinics in the UK (Fig. 1).
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The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist is provided as
Additional file 1.
Primary care (GP practices)
Primary care practices will involve the following:
1. Opportunistic identification of women presenting
with BV in GP practices which are VITA
recruiting centres with trained research staff on-
site. Participants will be identified, consented,
randomised and prescribed trial treatment at the
practice. These research-ready sites require on-
site availability of trained research nurses and fa-
cilities to directly consent and randomise
patients.
2. Opportunistic identification and referral of women
with BV attending GP practices without on-site re-
search staff, i.e. Participant Identification Centres,
to refer women presenting with BV to local partici-
pating VITA recruiting centres for invitation to par-
ticipate in the trial.
3. Pre-identification of women with a history of BV by
GPs from electronic patient records/primary care
databases. GPs will provide potential participants
with information on the trial via telephone or letter
and invite them to attend a local recruiting centre
for consent if they develop BV and are interested in
participating.
Secondary care
Secondary care practices will involve the following:
1. Opportunistic identification of women presenting
with BV in sexual health centres which are VITA
recruiting centres with trained research staff on-
site. Participants will be identified, consented, ran-
domised and dispensed trial treatment at the centre.
These research-ready sites require on-site availabil-
ity of trained research nurses and facilities to dir-
ectly consent and randomise patients.
2. Opportunistic identification of women presenting
with BV in gynaecology clinics which either (a) are
VITA recruiting centres with trained research staff
Fig. 1 VITA participant pathways in primary and secondary care settings
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on-site where participants would be identified, con-
sented, randomised and prescribed trial treatment
within the clinic, or (b) act as VITA referral clinics
(Participant Identification Centres) where women
presenting with BV may be referred to a nearby
participating recruiting sexual health centre for invi-
tation to participate in the trial.
Participants
The flow of participants from presentation through to
follow-up is shown in Fig. 2. Inclusion criteria are as
follows: age 16 years or over; clinical diagnosis of BV
based on patient-reported symptoms of discharge with
an unpleasant (typically fishy) odour (with or without
positive microscopy according to local site practice);
history of at least one previous episode of BV within
the past 2 years (clinically diagnosed or patient re-
ported) which resolved with treatment; willing to use
either intravaginal lactic acid gel or oral tablets for the
management of BV; willing to take own vaginal sam-
ples; willing to avoid vaginal douching during treat-
ment; willing to provide contact details and be
Fig. 2 Participant flow
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contacted for the purpose of collecting follow-up infor-
mation; willing to avoid sexual intercourse or use ef-
fective contraception for the 7-day duration of study
treatment (condoms are not considered to be effective
contraception due to a potential interaction with lactic
acid gel); access to the Internet and email and willing
to complete web-based follow-up questionnaires in
English; provision of written informed consent.
Exclusion criteria are as follows: contraindications or
allergy to lactic acid gel or metronidazole tablets; preg-
nant or breastfeeding; patients currently trying to con-
ceive; use of oral antibiotics (other than the study
treatment) or antifungal agents concurrently, within the
last 2 weeks or planned use within the next 2 weeks; use
of topical vaginal antibiotics, antifungals or acidifying
products (other than the study treatment) concurrently,
within the last 2 weeks, or planned use within the next 2
weeks; previous participation in this study; current par-
ticipation in another trial involving an investigational
medicinal product (IMP).
Contraindications and concomitant medications
Metronidazole
As per exclusion criteria, any known hypersensitivity to
metronidazole, other nitroimidazole derivatives or any of
the ingredients in metronidazole tablets will exclude pa-
tients from the trial. The metronidazole summary of
product characteristics (SmPC) gives further details, but
the following should be noted:
 Alcohol should be avoided (including products
containing alcohol) during the course of treatment
and for 48 h afterwards.
 Elevated international normalised ratio (INR) and
bleeding events have been reported with concurrent
use of warfarin and metronidazole.
Lactic acid gel
There is no SmPC for lactic acid gel, but the following
should be noted:
 Shellfish allergy: Some lactic acid gel brands may
contain glycogen obtained from oysters.
 Condom use: The effects of lactic acid gel on
condom degradation have not been fully
determined. Therefore, it is advised that condoms
should not be assumed to be an effective method of
contraception during the 7-day treatment period
with lactic acid gel.
Concomitant medications
Concomitant medications relevant to BV, such as oral or
topical antibiotics and/or antifungals, should be recorded
at baseline to determine patient eligibility. The use of
additional treatments is permitted after completion of
the 7-day study treatment at the discretion of the partic-
ipant’s physician.
Screening and consent
Women either pre-identified by, or presenting to, re-
ferring or recruiting GP practices, sexual health cen-
tres or gynaecology clinics with symptoms of BV will
be approached by a member of the site research team
to determine whether they are interested in partici-
pating in the trial. They will be given a verbal explan-
ation of the trial along with a Participant Information
Sheet, and they will have time to read this and ask
any questions about the trial prior to consent. Writ-
ten informed consent will be requested during the
same clinic visit.
Separate optional consent will be required for any
participants who are interested in taking part in the
qualitative telephone interview. Participants recruited
from sexual health centres and gynaecology clinics will
additionally be asked for their optional consent to
inform their GP that they are taking part in the trial.
Randomisation
Randomisation will take place in primary care (GP)
practices or outpatient sexual health/gynaecology
clinics. Participants will be randomised 1:1 to lactic acid
gel or metronidazole using a remote Internet-based
randomisation system developed and maintained by the
Nottingham Clinical Trials Unit (NCTU). The con-
cealed allocation system will use a minimisation algo-
rithm with the following variables and levels: site, type
of site (GP practice, sexual health clinic, gynaecology
clinic), number of episodes of BV in the previous 12
months (0, 1–3, > 3) and whether the participant has
had a female sexual partner in the previous 12 months
(yes/no). The allocation system will be created by the
NCTU in accordance with their standard operating
procedure (SOP) and held on a secure University of
Nottingham server.
As this is an open-label trial, there will be no blinding
of the participants, investigator, site research team or
trial team to treatment allocation. However, the central
laboratory staff performing BV microscopy and STI test-
ing will be blinded to the participants’ treatment alloca-
tion, and all analyses that present data separately by
treatment arm or that estimate between-group effects
will be conducted by a statistician blinded to treatment
allocation.
Trial intervention
There are two treatment arms within the trial:
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 Lactic acid gel; 5 ml to be inserted into the vagina
before bedtime once per day for 7 days
 Metronidazole tablets; 400 mg to be taken orally
twice daily, approximately 12 h apart, for 7 days.
Tablets should be swallowed whole, taken during or
after meals with a glass of water and not crushed or
chewed.
Investigational medicinal product
Metronidazole tablets are an IMP in the trial and are li-
censed for use in the treatment of BV as per the SmPC.
Medical device
Lactic acid gel is a registered medical device consisting
of a colourless viscous gel administered through an
intravaginal tube applicator. Known side effects of lactic
acid gel include vaginal irritation, e.g. redness, stinging
and itching. In rare cases an allergic skin reaction, e.g.
severe redness, swelling or burning, may occur.
Treatment supplies, labelling and storage
Participants will receive their study treatment via the
routine method of dispensing used in the setting of the
recruiting centre. In sexual health centres and gynaecol-
ogy clinics, this may be via issuance from standard clinic
stocks. In primary (GP) care practices, allocated treat-
ments may be issued via standard prescription as per
routine care. Participants will be advised to obtain their
allocated study treatment from any dispensing phar-
macy. Any licensed brands of metronidazole or lactic
acid gel may be used.
Trial-specific labelling will not be required, as the IMP
is being used within the terms of its marketing author-
isation in the UK. The IMP will be dispensed to a par-
ticipant in accordance with a prescription given by an
authorised healthcare professional and labelled in ac-
cordance with the requirements of Schedule 5 to the
Medicines for Human Use (SI 1994/31 94) (Marketing
Authorisations Etc.) Regulations 1994 that apply in rela-
tion to relevant dispensed medicinal products.
The IMP should be stored as per manufacturer’s in-
structions. Recruiting sexual health centres and gynae-
cology clinics should record batch number(s) and
manufacturer(s) of all allocated treatments.
Dosing schedule
Treatment should be started on the day of receipt, but
participants will be instructed to record their actual start
date and time (morning or evening) of dosing in their
patient diaries. Participants will also be asked to use
their patient diaries to log all subsequent doses taken
and/or missed doses over the treatment period in order
to aid compliance to the treatment schedule.
No treatment or dose modifications are expected in
this trial. Where a dose is accidentally missed, partici-
pants will be advised to follow the manufacturer’s in-
structions or seek advice from their physician. In the
case of any missed dose, participants will be advised to
continue to complete their treatment course.
Trial assessments and procedures
All assessments and procedures to be performed at
each time point for participants are indicated in Fig. 3.
Most assessments will be done at baseline, including
demographics, symptoms and previous BV episodes,
medical and sexual history, concomitant medications,
contraception and condom use, SF12™ Health Survey
and vaginal samples for BV/STI screening (sites will
send the baseline samples to a central laboratory at
University Hospitals Birmingham NHS Foundation
Trust which is accredited under the UK Accreditation
Service to perform the tests). After randomisation
into the trial, participants will then take their first
dose of trial treatment and continue taking trial treat-
ment for 7 days. At Week 2, participants will take
their own vaginal samples and send them to the cen-
tral laboratory. They will also complete a web-based
questionnaire with details of symptoms, treatment
adherence and tolerability, any known side effects,
healthcare use, additional BV treatments, sexual his-
tory, contraception/condom use and another SF12™
Health Survey. Participants will be asked to complete
a further two web-based questionnaires at 3 months
and 6 months with details of BV recurrence, sexual
history, healthcare use, additional BV treatments,
contraception/condom use and a final SF12™ Health
Survey (6 months only). Those not responding to
requests to complete web-based questionnaires will be
contacted by phone and/or text to collect follow-up
data.
Participants can discontinue trial treatment at any
time but can remain in the trial, taking Week 2 vaginal
samples and completing all follow-up questionnaires.
They can also withdraw from the follow-up assessments
at any time.
Qualitative telephone interviews
A subgroup of participants will be contacted for semi-
structured telephone interviews to explore acceptability
and adherence to trial treatment, and how these can be
optimised. A random sample of participants who gave
optional consent to be contacted will be recruited until
initial analysis suggests data saturation. The sample size
will then be reviewed to check that it is representative
of the trial target population in terms of age, ethnicity,
recruiting site and number of BV episodes. Where
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necessary, further participants will be recruited to en-
sure a diverse spread of the target population. The final
sample size is expected to be approximately 30 partici-
pants (15 in each trial arm). Interviews will be audio re-
corded, transcribed and uploaded into NVivo to assist
with data management. Transcripts will be coded and
analysed thematically.
Collection and analysis of vaginal samples
At the baseline visit, participants will be provided with a
kit for taking their own vaginal samples at Week 2. The
central laboratory will perform the following tests on vagi-
nal samples taken at baseline and at Week 2: microscopic
assessment of BV; nucleic acid amplification tests for chla-
mydia, gonorrhoea and trichomoniasis. Results will be
returned within 1–2months for the recruiting site to re-
view (investigator and research nurse) and to arrange fur-
ther testing or treatment according to local protocols.
These trial tests will not form the basis for patient man-
agement at the baseline visit; clinicians will take additional
tests processed locally to inform immediate patient care as
indicated by the patient’s clinical presentation.
Adverse events and pregnancy reporting
The safety profiles of the treatments in this trial are well
characterised. Metronidazole is being used for its li-
censed indication and lactic acid gel is being used within
its intended use covered by the CE mark. In order to
provide secondary outcome data to compare tolerability
of the two treatments, specified adverse reactions experi-
enced during trial treatment will be reported. The fol-
lowing are regarded as expected for the purpose of this
trial and will be reported on the Week 2 questionnaire
completed by the participant: nausea, vomiting, taste
changes, vaginal irritation, abdominal pain, diarrhoea.
Serious adverse events are not anticipated in this low-
risk trial but will be recorded if reported by participants.
Although lactic acid gel is considered safe for use in
pregnancy and metronidazole is frequently prescribed
for treatment of BV in pregnancy, patients will be asked
to confirm that they are not pregnant as part of the
screening process. Participants will also be asked to con-
firm their pregnancy status during their follow-up
period. Any pregnancies reported during the period be-
tween randomisation and Week 2 will be followed up
for outcomes.
Fig. 3 Summary of assessments at baseline and follow-up
Armstrong-Buisseret et al. Trials          (2019) 20:648 Page 8 of 12
Data management
All trial data will be entered on a trial-specific database
through the electronic Case Report Form (eCRF) with
participants identified only by their unique trial number
and initials. The database will be developed and main-
tained by the NCTU. Access to the database will be re-
stricted and secure, and all data transactions will be
logged in a full audit trail.
The NCTU will check site-completed eCRFs for com-
pliance with the protocol, data consistency, missing data
and timing. Sites will be asked for missing data or clarifi-
cation of inconsistencies or discrepancies.
Statistical considerations
Analysis of outcome measures
The analysis and reporting of the trial will be in accord-
ance with Consolidated Standards of Reporting Trials
(CONSORT) guidelines. A full Statistical Analysis Plan
will be developed and agreed prior to database lock and
unblinding of the analysing statistician. Continuous vari-
ables will be summarised in terms of the mean, standard
deviation, median, lower and upper quartiles, minimum,
maximum and number of observations. Categorical vari-
ables will be summarised in terms of frequency counts
and percentages. Descriptive statistics of demographic
and clinical measures will be used to assess balance be-
tween the randomised arms at baseline, but no formal
statistical comparisons will be made.
The primary approach to between-group comparative
analyses will be by the modified intention-to-treat
method, i.e. including all participants who have been
randomised and without imputation of missing outcome
data. Sensitivity analyses will be conducted to investigate
the impact of missing data and adherence to treatment.
The evaluation of the primary outcome will be per-
formed using a mixed effects model for binary outcome
that includes factors used in the minimisation. The com-
parison of lactic acid gel with oral metronidazole will be
presented using the risk difference in the proportion of
participants who reported resolution of symptoms at
Week 2, along with the 95% confidence interval (CI).
Secondary outcomes will be analysed using appropri-
ate regression models dependent on data type (binary,
continuous, count, survival, etc.) and will include factors
used in the minimisation and baseline value of the out-
come where measured. The analyses of secondary out-
comes will be considered supportive to the primary, and
estimates and p values, where presented, should be
interpreted in this light.
Presentation of quantitative tolerability data will be de-
scriptive. Frequency counts and percentages of the pro-
portion of participants reporting nausea, vomiting, taste
disturbance, vaginal irritation, diarrhoea and abdominal
pain will be presented by treatment arm.
Planned subgroup analyses
The primary analyses for symptom resolution will be in-
vestigated to determine whether treatment effectiveness
differs according to the following subgroups:
1. Presence of concomitant STI (yes/no)
2. BV confirmed by positive microscopy (yes/no)
3. Type of centre at which participant presented
(sexual health clinic versus GP/other clinics)
Between-group treatment effects will be provided for
each subgroup, but interpretation of any subgroup ef-
fects will be based on the treatment subgroup inter-
action and 95% CI, estimated by fitting an appropriate
interaction term in the regression models. Since the trial
is powered to detect overall differences between the
groups rather than interactions of this kind, these sub-
group analyses will be regarded as exploratory.
Planned interim analysis
There is no planned interim analysis of treatment effi-
cacy. However, an assessment of recruitment and adher-
ence to treatment will be performed using data from the
first 6 months of participant recruitment. This is done to
determine how feasible it is that the trial is able to ad-
equately address its primary and secondary objectives.
The Trial Steering Committee (TSC) and Data
Monitoring Committee (DMC) will use the following
criteria as a guide to determine whether the trial
should progress:
1. Reviewing the number of participants completing
their Week 2 assessment against the following
targets:
 > 90%, continue the trial
 65–90%, review recruitment and retention
procedures to identify underlying problems and
implement strategies to address these problems,
with review in 6 months
 35–65%, review recruitment and retention
procedures to identify underlying problems and
implement strategies to address them. Ongoing
review over 6 months; terminate the trial if the
recruitment trajectory does not indicate that full
recruitment can occur within an acceptable
recruitment period
 < 35%, terminate the trial.
2. Reviewing adherence to lactic acid gel and
metronidazole against the following pre-defined
targets:
 Median adherence 5–7 days per week, continue
the trial
 Median adherence 3–4 days per week, review
data from the qualitative interviews on
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adherence and tolerability to identify underlying
problems and implement strategies to address
them, with review in 6 months
 Median adherence < 3 days per week, terminate
the trial.
Power calculation/sample size calculation
Assuming that 80% of participants receiving oral
metronidazole achieve resolution of symptoms, 1710
participants are required for analysis to detect a 6%
increase in response rate to 86% in participants re-
ceiving lactic acid gel (risk ratio 1.08) at the 5% SL
(two-sided) with 90% power.
To allow for non-collection of the primary outcome
from up to 10%, e.g. due to loss to follow-up, a total of
1900 participants will be recruited.
Health economics
The economic analysis will compare the costs associated
with the current standard treatment, metronidazole, with
those of the proposed alternative treatment, lactic acid
gel, in the treatment of BV.
The economic evaluation will adopt the perspective of
the NHS, and data on resource use and costs will be col-
lected prospectively within the study. Resource use data
will be collected prospectively via nurse/assessor/partici-
pant completed forms and will include questions on
treatment use, GP or other clinic visits to estimate the
costs associated with the administration of both treat-
ments. The main resources to be monitored include: (1)
additional staff time for explaining the lactic acid inter-
vention and responding to concerns associated with
treatment; (2) time and resources associated with clinical
examination, additional medication and monitoring dur-
ing the follow-up period as well as treating any adverse
events; (3) the costs associated with treatment, for ex-
ample the costs of lactic acid gel and applicators.
Information on unit costs or prices will be attached to
each resource item in order that an overall cost per patient
successfully treated at 2 weeks, 3 months and 6months
can be calculated, and a cost per quality-adjusted life year
(QALY) at 26 weeks. The cost associated with antibiotic
resistance to add as a penalty cost for using antibiotics has
been estimated [22], and within this study we will explore
whether a similar approach could be taken.
Outcomes will be measured in natural units according
to assessment of symptoms of BV at 2 weeks, 3 months
and 6months post intervention.
Qualitative data analysis
Data from participant interviews will be coded thematic-
ally, with codes based on interview questions and emer-
gent themes. Coded data will be compared between
participants in the same arm of the trial, and between
trial arms, and will be synthesised using a framework
approach.
Trial governance
The Trial Management Group (TMG) are responsible
for day-to-day management of the trial, including review
of protocol deviations entered into the eCRF. The TMG
include the Chief Investigator, Trial Manager, Trial Stat-
istician and other members of the NCTU multidisciplin-
ary team as appropriate. The TMG are responsible for
ensuring project milestones are achieved.
A TSC has been established, and their role is to pro-
vide trial oversight, monitor trial progress and conduct
and advise on scientific credibility. The TSC will con-
sider and act, when appropriate, upon the recommenda-
tions of the DMC. The role of the DMC is to monitor
accruing data and make recommendations to the TSC
on whether there are any ethical or safety reasons why
the trial should not continue.
Discussion
This trial uses a pragmatic design to maximise its rele-
vance to clinicians and participants, to help ensure
rapid adoption into clinical practice and to provide
value for money. If effective, the use of lactic acid gel
will provide an alternative treatment for women who
have failed to respond to previous therapy for BV,
benefitting both patients and the NHS. It will also re-
sult in decreased antibiotic use, which will maintain the
balance of the gut bacteria (microbiome) for individu-
ally treated participants in addition to reducing the po-
tential for the development of antimicrobial resistance
in the community. This is an important area for clinical
research, and results from the trial will help inform UK
treatment guidelines for BV in addition to supporting
the Department of Health’s Antimicrobial Resistance
Strategy [23].
Trial status
The protocol is version 1.0, dated 29 June 2017. Recruit-
ment opened on 30 October 2017 and is expected to con-
tinue to 30 November 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3731-7.
Additional file 1. VITA SPIRIT 2013 checklist: recommended items to
address in a clinical trial protocol and related documents.
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